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Abstract: Accumulating evidence points to a link between circadian clock dysfunction and the
molecular events that drive tumorigenesis. Here, we investigated the connection between the
circadian clock and the hallmarks of cancer in an in vitro model of colorectal cancer (CRC). We used a
cross-platform data normalization method to concatenate and compare available microarray and
RNA-sequencing time series data of CRC cell lines derived from the same patient at different disease
stages. Our data analysis suggests differential regulation of molecular pathways between the CRC cells
and identifies several of the circadian and likely clock-controlled genes (CCGs) as cancer hallmarks
and circadian drug targets. Notably, we found links of the CCGs to Huntington’s disease (HD) in the
metastasis-derived cells. We then investigated the impact of perturbations of our candidate genes
in a cohort of 439 patients with colon adenocarcinoma retrieved from the Cancer Genome Atlas
(TCGA). The analysis revealed a correlation of the differential expression levels of the candidate genes
with the survival of patients. Thus, our study provides a bioinformatics workflow that allows for a
comprehensive analysis of circadian properties at different stages of colorectal cancer, and identifies a
new association between cancer and HD.
Keywords: circadian clock; colorectal cancer; drug targets; high-throughput time course data;
Huntington’s disease
1. Introduction
Multiple biological processes that drive the onset and progression of malignant growth have
been extensively investigated and termed as hallmarks of cancer [1]. These hallmarks represent
key biological events that are rewired by tumors and favor survival of malignant cells in the host
tissue. Accumulating evidence highlights the need of targeting these molecular alterations in cancer
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treatment [2,3]. Although available chemotherapeutic treatment strategies have been partially successful
in eliminating cancer cells, the resulting severe side effects (i.e., fatigue, hypertension and liver toxicity),
increased therapy resistance and relapse of disease reveal the diversity of therapeutic outcome due to
inter- and intra-patient variability [4]. These findings have directed the cancer research field towards
the development of patient-specific treatment strategies [5].
A promising link has been reported between the circadian clock and the key molecular events
that contribute to tumorigenesis [6,7], which is likely to provide a promising temporal component
to personalized therapy [8]. The mammalian circadian clock describes an internal, self-sustained
timekeeping mechanism that regulates many aspects of physiology and behavior [9], and enables
organisms to anticipate and respond to environmental changes such as light-dark cycles [10].
This ensures the appropriate timing of biological processes including the regulation of core body
temperature, sleep/wake cycles, immunological activity and metabolism [11,12].
At the cellular level, the circadian clock is driven by transcriptional and translation feedback
loops (TTFLs) [13,14], comprising gene and protein families of transcriptional repressors (PER, CRY,
REV-ERB) and activators (CLOCK, BMAL, ROR) [15,16]. These elements drive 24 h rhythmic oscillations
in the expression of target genes, the so-called clock-controlled genes (CCGs). Oscillations of core-clock
genes and CCGs affect various cellular mechanisms, including the cell cycle, DNA damage response,
and cell death, which contribute to tumor initiation and progression [17–19]. In a healthy cellular state,
the cell cycle is regulated strictly to protect genomic fidelity during DNA synthesis and cell division [20].
Circadian regulation of the cell cycle was reported to occur via the modulation of cell cycle checkpoints
such as the Wee1 kinase [21] that regulates G2-M transition, Myc [22,23], p53 [24,25], p21 [26], and
p16 [27,28]. Disruption of core-clock components was found to be associated with accelerated tumor
growth in several mouse models including malignant lymphoma [29], lung [30], colorectal cancer [26],
ovarian, pancreatic, and intestinal cancer [18].
The investigation of, potentially dysregulated, clock phenotypes in cancer requires the analysis of
circadian rhythmicity at the transcriptome level. Although the availability of high-throughput cancer
data sets has increased in the last years, most of this data was obtained at a single time point rather
and not sampled over a circadian day and is thus inadequate for circadian analyses.
In the current study, we illustrate the link between the circadian clock and the hallmarks of cancer
in a meta-analysis of an in vitro model of colorectal cancer (CRC). For our analysis, we used available
microarray and RNA-sequencing (RNA-seq) time series data of two cell lines that are derived from a
primary tumor (SW480) and a lymph node metastasis (SW620) of the same patient. We developed a
data analysis workflow for the cross-platform comparison and concatenation of the time series datasets.
This yielded a longer time-series and allowed for more robust results concerning circadian gene sets,
related circadian parameters and the subsequent analysis regarding significantly phase-clustered
biological pathways and relevant clock-regulated genes in the tumorigenesis process.
In the concatenated data set, we identified robust sets of 24 h rhythmic genes. A phase set enrichment
analysis (PSEA) revealed phase-clustered biological pathways that differ between the primary tumor
and the metastasis-derived cells. In SW480 cells, enriched biological pathways included DNA repair
mechanisms, proliferative pathways such as MAPK, WNT, and JAK-STAT and immunological response
such as antigen presentation. In the metastasis-derived SW620 cells, biological pathways that are
known to play a role in transcriptional regulation (i.e., RNA polymerase, basal transcription factors and
ubiquitin-mediated proteolysis) were enriched for circadian genes with similar phases. Surprisingly,
we also found phase-clustered pathways related to Huntington’s disease (HD) in the metastatic
cells. We extended our rhythmicity analysis to identify circadian drug target genes [31] and found
19 oscillating drug targets in total. In particular, we showed that MTOR and AKT1 are oscillating in
our data sets and associated to the circadian clock, cancer hallmarks and circadian drug targets.
We studied the impact of candidate genes from the merged lists for the extended core clock
network (ECCN) [32], HD, cancer hallmarks and circadian drug targets in an independent colon
adenocarcinoma clinical study that was obtained from TCGA. We plotted a graphical summary of
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mutational frequencies in colon adenocarcinoma patients (439 samples). Although we could not
observe a significant impact on patient survival, our results showed that 4 of the top frequently mutated
candidate genes were also involved in HD. These candidate genes were HSPH1, HTT, SIN3A, and
CLTC. Alterations in expression of our candidate genes showed correlation with patient survival in
core clock components PER3, NR1D1, and CSNK2A1 and angiogenesis related VEGFA. Furthermore,
our analysis highlights the link between the core-clock genes to cancer hallmark genes such as AKT1,
MTOR, and MYC based on the literature. Further investigation of these genes might be helpful to
establish alternative treatment regimens for cancer patients by considering the circadian clock.
2. Results
2.1. Correlation of Gene Expression between Circadian Microarray and RNA-seq Data of Human CRC Cell Lines
We evaluated the circadian transcriptome in an in vitro CRC progression model of the CRC cell
lines SW480 and SW620, previously profiled by time-series DNA microarrays [33] and RNA-seq of
mRNAs [34], and aimed to concatenate the datasets to gain a longer and more robust circadian time
series in order to explore putative cancer-relevant circadian pathways. The microarray dataset consists
of nine samples that were taken from 0 to 24 h after synchronization of the cells by medium change,
whereas the eleven RNA-seq samples were taken from 12 to 42 h after synchronization. Both the
samples from the microarray, as well as from the RNA-seq datasets were previously produced by our
group. Different methods can be used to synchronize the cell population before circadian measurements
(e.g., serum shock, use of dexamethasone), and we previously tested different synchronization methods
for these cells [27,35–37]. As a simple medium change led to comparable results in our cell lines,
we decided to use the simplest and less interfering way for cell synchronization [33,34,38]. For the
generation of the data sets used in the work, cells were synchronized by medium change.
The microarray dataset covers a full circadian cycle with one additional time replicate of the first
time point (0 h = 24 h) and the RNA-seq datasets covers 1.25 circadian cycles with time replicates of
three time points (12 h = 36 h; 15 h = 39 h; 18 h = 42 h).
Both datasets were re-analyzed and compared to investigate how well 24-h rhythmic genes,
associated circadian parameters, and circadian pathways are replicated across platforms (Figure 1).
While for microarray data, the Robust Multi-array Average (RMA) method is commonly used to gain
expression values, no standard method for the pre-processing of circadian RNA-seq data has so far been
established [39]. For this reason, a tripartite pipeline was used for the alignment and quantification
of the raw RNA-seq reads: Two of the chosen pipelines employ the STAR aligner for the alignment
of the raw reads to the human genome. Subsequently, the aligned reads were either quantified by
featureCounts (STAR + featureCounts) or by Salmon in alignment-based mode (STAR + Salmon). In the
third pipeline, reads were directly quantified by Salmon in quasi-mapping-based mode (Salmon).
The average mapping rates of STAR (81.7% ± 2.55) and Salmon (87.1% ± 0.95) are comparable and
consistent across time points and cell lines (Figure S1A). An expression cut-off of at least 0.5 CPM per
gene on average over all time points resulted in 13,904 to 16,478 expressed genes in SW480 cells and
13,495 to 15,933 expressed genes in SW620 cells, depending on the pre-processing method (Figure S1B).
For both cell lines, STAR + featureCounts yields the highest number of expressed genes, followed by
STAR + Salmon. Independent of the chosen method, the number of expressed genes in SW480 cells is
higher than the respective number in SW620 cells. Analogously, different cut-offs for expressed genes
were compared for the microarray data, resulting in 21,798 expressed genes with a minimum mean
log2 RMA-pre-processed intensity value of 3 across all time points in SW480 cells and 21,764 genes in
SW620 cells (Figure S1C). Since there are no universal cut-offs to exclude genes with low expression
values either for microarray intensity values or RNA-seq counts, the chosen cut-offs are arbitrary and
could be adjusted to gain expressed gene sets of comparable sizes for the different platforms. For the
present study, this is not necessary because we focus on genes that are commonly expressed across
platforms in subsequent correlation and rhythmicity analyses.
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Figure 1. Workflow for the comparison of time-series microarray and RNA-seq data from human
colorectal cancer (CRC) cell lines. Two circadian datasets (microarray and RNA-seq) for the cell
lines SW480 and SW620 were pre-processed to determine gene expression values. For the RNA-seq
data, three different methods (STAR + featureCounts, STAR + Salmon, Salmon) for the alignment and
quantification of reads were applied to determine gene expression values. A correlation analysis for
shared time points revealed which RNA-seq pre-processing method yields expression values that
correlate best with the microarray expression. The best-correlated RNA-seq expression dataset was
then TDM-transformed to the range of the microarray data and both datasets were concatenated to
gain a longer time-series. 24 h rhythmic gene sets were determined based on the three different sets of
data (microarray, RNA-seq and concatenated). Biological pathways enriched for the 24 h rhythmic
genes of the concatenated dataset were determined and investigated with view to hallmarks of cancer.
For all commonly expressed genes and shared sampling time points, we compared the resulting
RNA-seq expression values to each other and to the microarray expression values in a correlation
analysis (Figure 2A). Expression values determined by the three RNA-seq analysis pipelines have
high mean Pearson correlation coefficients among each other (> 0.9) and are similar across cell lines.
We observed the highest correlation between STAR + Salmon and Salmon for both cell lines, indicating
that the alignment/quasi-mapping step has a smaller impact on resulting gene expression values
than the subsequent quantification of the mapped reads. The mean correlation coefficients between
the three RNA-seq pipelines and the microarray data are very similar across methods and cell lines
as well, but lower (ranging from 0.72 to 0.74). This result indicates that the choice of the RNA-seq
analysis pipeline does not have a large influence on the correlation coefficients, which are primarily
determined by the chosen platform. Nonetheless, since the highest correlation of the three pipelines
with the microarray data is observed for the STAR + Salmon analysis for both cell lines, we consider
the STAR + Salmon dataset to represent the best approximation to the microarray data for subsequent
analyses and hereafter denote it as “RNA-seq data”.
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Figure 2. Correlation of gene expression and intersection of 24 h rhythmic gene sets between circadian
microarray and RNA-seq data of human CRC cell lines. (A) Mean Pearson correlation coefficients
between expression values determined by different platforms and different downstream methods for
SW480 cells (left panel) and SW620 cells (right panel). Expression values were determined based
on microarray data and RNA-seq data (Salmon, STAR + featureCounts, STAR + Salmon). Shown are
the mean Pearson correlation coefficients between gene expression values determined for identical
time points (12–24 h since synchronization). (B) Number of 24 h rhythmic genes for SW480 cells (left
panel) and SW620 cells (right panel) based on the three datasets (microarray: green; RNA-seq: pink;
concatenated: blue) as determined by harmonic regression for different q-value cut-off and a relative
amplitude cut-off of 0.1. The grey rectangle marks the cut-off chosen to determine 24 h rhythmic gene
for subsequent analyses. (C) Intersections between 24 h rhythmic gene sets in SW480 cells (left panel)
and SW620 cells (right panel) identified based on microarray data (green), RNA-seq data (pink) and the
concatenated expression of both methods (blue).
2.2. Cross-Platform Concatenation of Time Series Reveals Robustly Circadian Gene Sets for SW480 and
SW620 Cells
Since the microarray and RNA-seq datasets contain overlapping but not identical time series, a
concatenation of the data would yield a longer time series of nearly two circadian cycles (42 h) with a
consistent sampling resolution of 3 h. However, independent of the correlation of gene expression,
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the range of the abundance measure of the two methods is different: while microarrays measure
fluorescence intensities and yield RMA-pre-processed expression values in a log2-scaled range from
0 to 13.5, RNA-seq quantifies gene expression in CPM in a higher dynamic log2-range from −8 to
15 (Figure S2A). To circumvent this dataset shift and to make expression values comparable across
platforms, we applied TDM-normalization to the RNA-seq data [40]. The TDM method transforms an
RNA-seq dataset to have a similar distribution as a microarray dataset while keeping inter-observation
dependencies intact. Indeed, the distribution of the TDM-transformed RNA-seq expression data closely
resembles that of the microarray data for both cell lines (Figure S2A). However, when comparing
mean expression levels over the complete time series of individual genes, we still observe a tendency
for a lower mean expression of lowly expressed genes and a higher mean expression of highly
expressed genes for the RNA-seq data which is likely due to its higher dynamic range (Figure S2B).
Nonetheless, for the bulk of genes, the gene expression values of both platforms are comparable after
the TDM-transformation of the RNA-seq data, thus allowing for a concatenation of the datasets.
We applied the harmonic regression method to identify 24 h rhythmic gene sets for all three
datasets, using an FDR of 5% and a relative amplitude cut-off of 0.1 (Figure 2B). When comparing the
overlaps between the 24-h rhythmic gene sets identified based on the two different platforms and the
concatenation of both, it becomes apparent that both the number and the identity of rhythmic genes
differ greatly between the methods (Figure 2C). The intersection of all three datasets only amounts
to 110 (2.3%) genes commonly identified as 24 h rhythmic in SW480 cells and 52 (1.5%) in SW620
cells. For both cell lines, few genes were commonly identified as rhythmic by the microarray and
RNA-seq data but not by the concatenated data, indicating that the concatenation of the two-time
series successfully captures the circadian transcriptome identified by either one of the platforms.
Additionally, many genes were identified as significantly 24 h rhythmic in the concatenated data
that were not detected in either one of the two shorter time series, possibly capturing false negative
circadian genes. Contrary to expectations and previous results gained from the microarray data [33],
more 24 h rhythmic genes were identified for SW620 cells (728) than for SW480 cells (564) based on the
RNA-seq data. In contrast, we detected a higher number of 24 h rhythmic genes in SW480 (3426) than
in SW620 cells (1892) based on the concatenated dataset.
In the next step, we compared circadian parameters in a gene-wise manner for all genes that were
identified to be 24 h rhythmic in the same cell line in at least two of the datasets. The phases estimated
based on microarray and RNA-seq data of SW620 cells have a lower absolute circular Pearson correlation
coefficient (0.05) than those estimated for SW480 cells (0.26) and are not significantly correlated (p = 0.58)
(Figure S3A). The correlation between the phases estimated based on the concatenated data and the
microarray data is much higher (circular Pearson correlation coefficient 0.99 for SW480 cells and 0.85
for SW620 cells) and significant (p < 0.05) (Figure S3B), as is the correlation between the concatenated
phases and the RNA-seq phases (circular Pearson correlation coefficient 0.95 for SW480 cells and
0.87 for SW620 cells) (Figure S3C). The lowest gene-wise correlation of relative amplitude values was
observed between amplitudes estimated based on the RNA-seq and the microarray data for both
cell lines (Pearson correlation coefficient 0.28 for SW480 cells and 0.20 for SW620 cells) (Figure S3D).
The amplitude correlation is highest between the microarray and the concatenated data (Pearson
correlation coefficient 0.83 for SW480 cells and 0.77 for SW620 cells) (Figure S3E) and considerably
lower between RNA-seq data and concatenated data (Pearson correlation coefficient 0.32 for SW480
cells and 0.48 for SW620 cells), where a trend for higher amplitudes can be observed for the RNA-seq
data (Figure S3F). Overall, the cross-platform concatenation of time series yielded 24-h rhythmic gene
sets with more robust circadian parameters than simply comparing circadian gene sets separately
derived from microarray and RNA-seq data.
We visualized the expression of the complete set of 24 h rhythmic genes identified based on the
concatenated data across platforms by phase-ordered heatmaps (Figure 3A). Gene expression of the
overlapping time points is very similar between microarray and RNA-seq data, indicating that the
cycling genes are indeed reproducible across platforms. However, for the RNA-seq data, the second
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peak/trough of expression is less distinct than the first for both cell lines. This might be due to the fact
that the heatmaps are ordered according to the phase estimated based on the concatenated data set
and not based on the individual platforms. Alternatively, it could also result from a progressive loss of
synchrony between the cells due to the lack of a synchronizing stimulus. Five out of the top ten 24 h
rhythmic genes identified for SW480 cells based on the concatenated data are core clock genes: BMAL1,
NR1D1, NR1D2, PER2, and PER3 (Figure 3B). All display very similar oscillations between the two
platforms, indicating that the normalization and concatenation of the data is suitable for the detection of
robustly circadian genes. No core clock genes are detected among the top ten 24-h rhythmic candidate
genes detected in SW620 cells (Figure 3B), but one of the candidate genes, CDC25A, is a target of
the core clock protein NPAS2 and known to promote cell survival of hepatocellular carcinoma [41].
The candidate circadian gene NUP153 which is encoding for a nuclear pore protein has been found
to be involved in the control of the nuclear translocation of the Drosophila clock proteins PER and
TIM [42].
Figure 3. Concatenation of samples from circadian microarray and RNA-seq datasets reveals robustly
24-h rhythmic genes across platforms. (A) Range-normalized, phase-ordered microarray (respective
left panel) and RNA-seq expression (respective right panel) heatmaps of genes that were identified
as 24-h rhythmic in SW480 cells (two leftmost panels) and SW620 cells (two rightmost panels) in the
concatenated data. Each row represents one gene. Phases were estimated based on the concatenated
data. Black rectangles mark the shared time points between the microarray and the RNA-seq data.
(B) Normalized time-series expression of the top ten 24 h rhythmic genes identified in SW480 cells (top
row) and SW620 cells (bottom row) based on the concatenated data. Microarray expression values
are represented by green lines and RNA-seq expression values by pink lines. The blue area marks the
confidence area of the harmonic regression fitted to the concatenated data for 24-h rhythmic genes.
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2.3. Oscillatory Expression of Cancer Hallmark-Associated Genes and Drug Target Genes Differs between the
CRC Cell Lines
We used the PSEA to identify significantly phase-clustered biological pathways enriched for
the 24 h rhythmic genes in SW480 and SW620 cells (q < 0.05 determined by Kuiper test against
a uniform distribution). While for SW480 cells, enriched pathways had mean phases distributed
across the whole circadian cycle from 0 to 23.6 h, phases were clustered between 4.5 and 10.3 h, for
SW620 cells. For both CRC cell lines, the enriched pathways included cancer-relevant processes,
such as cell cycle, DNA repair, and DNA replication (Figure 4A). Several of the pathways have
previously been identified to be phase-clustered based on the microarray data, though partly with
different phases [33]. Other biological pathways enriched in SW480 cells were involved in extracellular
matrix organization and intercellular communication, immune response, growth pathways such
as MAPK and DNA damage response (Figure 4A). In SW620 cells, the analysis showed enriched
biological processes involved in protein biosynthesis and the structure of plasma membrane (Figure 4B).
Interestingly, several neurodegenerative diseases and neuronal communication pathways were also
enriched in SW620 cells. These included Alzheimer’s disease (AD), Parkinson’s disease (PD), and
Huntington’s disease (HD). These disorders are characterized by neurodegeneration and commonly
show dysregulation of circadian rhythms of physiological and behavioral processes, such as hormone
secretion, blood pressure, body temperature, activity, and sleep-wake cycle [43]. Notably, HD has been
associated with lower cancer risk [44,45]. HD is caused by a CAG trinucleotide repeat expansion in the
huntingtin (HTT) gene, resulting in a protein with an expanded polyglutamine tract. Although HD is
caused by the mutation of one single gene, multiple other genes have been reported to contribute to
the HD pathogenesis. Pathways usually described as linked to HD include cytotoxicity, apoptosis,
and calcium signaling, but processes and pathways associated with cancer such as cell cycle, RNA
splicing, Wnt, and erbB signaling are also significantly enriched in HD patients and mouse models of
the disease [46]. For this reason, we next explored whether HD-related genes were oscillating in our
dataset (Figure 4C,D). We extended our enriched gene set for HD retrieved with the PSEA analysis
(25 genes, Table S1), to include two well-known HD-associated genes from the literature HTT [47]
and HSPH1 (Heat shock protein family H (Hsp110) member 1), which has been shown to suppress
or disaggregate HTT fibrils [48]. This resulted in a set of 27 genes that oscillate significantly in either
of the cell lines, which represent about 13% of the total HD-KEEG pathway (hsa05016, 199 genes).
In addition to their role in HD, elements from this gene set are also involved in processes such as
mitochondrial metabolism, cellular survival and transcriptional regulation.
From the extended HD-related genes list 26 genes were oscillating in SW620 cells: CASP3, CLTC,
CREB3L4, CYCS, DLG4, GNAQ, HIP1, HSPH1, NDUFA2, NDUFA4, NDUFA4L2, NDUFAB1, NDUFS3,
POLR2C, POLR2D, POLR2K, PPARG, SDHD, SIN3A, SOD2, TAF4B, TBP, TBPL1, TP53, UQCR10, and
UQCRHL (Figure 4D). In contrast, for the primary tumor cell line SW480, only 3 genes (HIP1, HSPH1,
HTT) showed significant oscillations (Figure 4C). We observed that among these candidates only HIP1
and HSPH1 depicted significant circadian oscillations in both SW480 and SW620 cells.
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Figure 4. Phase-clustered circadian pathways in SW480 and SW620 cells. Circadian-phase-clustered
KEGG pathways enriched for 24 h rhythmic gene sets identified for SW480 cells (A) and SW620 cells
(B). The colors represent the vector-average phases of the pathways. Normalized time series expression
of the HD associated genes (27 genes) in SW480 cells (C) and SW620 cells (D) based on the concatenated
data. Microarray expression values are represented by green lines and RNA-seq expression values by
pink lines. The blue area marks the confidence area of the harmonic regression fitted to the concatenated
data for 24 h rhythmic genes.
We further investigated whether the 24 h rhythmic gene sets of either cell lines included circadian
cancer hallmark-associated genes as described by Sulli and colleagues [7] (see also Table S3) and/or
circadian drug target genes from Dallmann and colleagues [31]. In SW480 cells, we found 13 cancer
hallmarks-associated genes to be 24 h rhythmic: AKT1, ATM, DGAT2, EGLN1, MTOR, MYC, NFE2L2,
PARP1, SIRT1, TGFB1, VEGFA, and XPA (Figure 5A). In SW620 cells, we found six genes to be circadian
expressed (AKT1, MTOR, SIRT1, PPARG, SOD2, TP53) among the cancer hallmarks-associated set, and
three of the genes (AKT1, MTOR, and SIRT1) were also oscillating in SW480 cells (Figure 5B). On the
other hand, several of the candidate genes are also part of the phase-clustered pathways identified
to be enriched for 24 h rhythmic genes in SW480 cells (Figure 5C). From the list of circadian drug
target genes [31], we found 19 drug target genes to be oscillating in either SW480 or SW620 cells
(Figure 5D,E), including AKT1 and MTOR that were significantly rhythmic in both cell lines. In SW480
cells, two members of the RAS gene family, NRAS and RRAS, showed circadian rhythms, whereas
circadian drug targets in SW620 cells included the genes ABCB1 and ABCC2 that encode for multidrug
resistance-associated proteins.
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Figure 5. Cancer hallmark-associated and drug target genes show differing oscillatory expression
in SW480 and SW620 cells. Normalized time series expression of cancer hallmark-associated genes
identified as 24 h rhythmic in (A) SW480 and (B) SW620 cells based on the concatenated data.
(C) Phase-clustered circadian KEGG pathways in which cancer hallmark-associated genes are involved
in SW480 cells. Normalized time series expression of drug target genes identified as 24 h rhythmic
in (D) SW480 and (E) SW620 cells based on the concatenated data. Microarray expression values are
represented by green lines and RNA-seq expression values by pink lines. The respective top row shows
the expression in SW480 cells and the respective bottom row in SW620 cells. The blue area marks the
confidence area of the harmonic regression fitted to the concatenated data for 24 h rhythmic genes.
Next, we merged the circadian cancer hallmark-associated gene set (Figure 5A,B) with the list of
27 genes associated with HD curated from PSEA results and literature (Figure 4B,C) and the circadian
drug targets (Figure 5D,E) which results in a list of 55 candidate genes (Table S2). Additionally, we
included into our analysis elements of the extended core clock network (ECCN) which was previously
assembled by our group [32], which were significantly oscillating (in either of the cell lines) within
our concatenated data set (Table S4). We analyzed the mutational frequencies from a cohort of colon
adenocarcinoma patients [49,50] (439 samples from the PanCancer study) from the TCGA database, as
depicted in the OncoPrint graphical summary of our candidate gene set (Figure S4). The top candidate
genes with the highest frequency of mutations (cut-off of 4%) were depicted in Figure 6A. Among
the most frequently mutated candidates we found genes known to be associated with cancer (TP53,
PIK3CA, and ATM), core-clock genes (PER1, PER3, and ARNTL), and elements of the ECCN (CREBBP
and EP300) (Figure 6A).
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Figure 6. Mutational frequencies and impact of candidate genes on overall survival in TCGA COAD
cohort (A) Oncoprint graphical summary of alterations in candidate genes that are mutated more than
4% of patients (B) Cox-regression based survival curves based on gene expression of candidate genes.
Interestingly, we observed that four HD-associated genes, namely TP53, HTT, SIN3A, and CLTC
were listed among the top frequently mutated candidate genes. In order to assess the impact of the
candidate genes on patient survival we performed a differential expression analysis (FDR 0.05, logFC
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1.5) using paired tumor and adjacent normal tissue samples (Table S5). The intersection of differentially
expressed genes (DEG) and our list of candidate genes, resulted in 12 elements including cancer
associated genes (NRAS, MYC, and VEGFA), circadian drug targets (SOD2 and CES2) and core-clock
and ECCN genes (AHR, CREB1, CSNK2A1, NFIL, NPAS2, NR1D1, and PER3) (Table S5). Our analysis
showed that the variations in gene expression in some of these genes were significantly associated
with patient survival (Figure 6B). In order to access high and low risk groups based on gene expression
changes, we selected for each gene the top and bottom thirds of the patient population (n = 145 low,
n = 145 high) as representing high and low expression groups, respectively. The core-clock genes
NR1D1, PER3, CSNK2A1, and the cancer associated gene VEGFA showed statistically significant results
in our Cox-regression based survival plots (log rank test p ≤ 0.05).
Although not all core-clock genes were among the most frequently mutated genes within our
list, an indirect contribution of the circadian clock on these genes was possible. Thus, we created a
diagram including both cancer-associated and circadian drug target genes that were oscillating in our
concatenated data sets (Figure 5E). To more precisely illustrate the mechanistic link between these
genes and the core-clock genes, we carried out a curated literature search for the interactions between
core-clock and cancer-hallmark target genes (Table S3). For SW480 cells, we found a unique set of
oscillating genes, namely NFEL2L, PIK3CA, ATM, TGFB1, DGAT2, EGLN1, MYC, PARP1, VEGFA,
and XPA. For SW620 cells, we found PPAR-G, SOD2, and TP53 to be 24 h rhythmic only in this cell
line (Figure 7A). SIRT1, AKT1, and MTOR oscillate in both cell lines in a circadian manner and are
associated with the circadian clock and cancer hallmarks (Figure 7A). In addition to the connection
to cancer hallmarks and circadian drug targets, some of the circadian genes found in SW620 cells
were associated with HD (Figure 4C). We illustrated these HD interaction links in our diagram which
included PPARG, SOD2, and TP53 (from the work of Sulli and colleagues [7]). and NDUFS3, which is
indirectly linked to cellular energetics, often dysregulated in cancer (Figure 7A). We further included
circadian drug target genes that are oscillating in SW480 and SW620 cells (Figure 7B). As we linked all
the interactions between the core-clock genes, cancer hallmarks and circadian drug target genes, we
observed that AKT1 and MTOR were circadian expressed, drug target genes, in both cell lines.
Figure 7. Cont.
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Figure 7. Graphical illustration of molecular interactions between the core-clock network, genes
involved in hallmarks of cancer and circadian drug targets. (A) Target genes associated with cancer
hallmarks and the circadian clock that were found oscillating in analysis. For genes that have multiple
route to interact with the clock genes the numbered arrows indicate all potential interaction ways of
the target genes to the core clock genes. (B) Circadian drug target genes oscillating significantly in
analysis. Additionally, some of the candidate cancer associated genes in the diagram were also linked
to Huntington’s disease (Table S1). These genes are highlighted with beige and negative regulators of
the core circadian clock machinery with black circles. NDUFS3 is indirectly associated with the cancer
but dominantly found in HD. “~” stands for significantly oscillating genes and dashed lines indicate
the presence of indirect links to the circadian clock machinery.
3. Discussion
CRC is one of the most common types of cancers of the digestive system [51]. One promising
new approach in CRC treatment is the time-dependent administration of chemotherapeutic drugs in
agreement with the chronotype of the patient [52–54]. Accumulating evidence points to an association
between malfunctions of the circadian clock and biological events that drive tumorigenesis [6]. Extensive
research at the genome-wide level concerning the existence of a putative circadian dysregulation in
cancer suggests a role of the core-clock and clock-controlled genes in various biological processes
involved in cancer onset and progression [55,56]. However, most of the available data was sampled
at a single time point, thereby precluding a detailed assessment of circadian effects. Due to the high
cost and effort of producing densely sampled time series data, the meta-analysis of legacy datasets
is common in the circadian field. Simulations with synthetic time series have shown that sampling
periods shorter than two full circadian cycles can lead to an increase of the false negative rate [57]. Yet,
not all circadian datasets fulfil these requirements. Moreover, in recent years, the technical platforms
used for gene expression profiling have increasingly shifted from microarrays to RNA-seq. In order to
attain more robust results concerning the identity of circadian genes and their rhythmic parameters, e.g.,
as training data for machine learning approaches [41], it could prove beneficial to extract information
from both microarray and RNA-seq legacy datasets.
3.1. Cross-Platform Concatenation of Time Series Reveals Differential Circadian Expression in a CRC Model
In the present study, circadian datasets originating from the same CRC cell line model were
normalized and concatenated across platforms, yielding a longer time series with two replicate
measurements for overlapping time points. For both cell lines, the rhythmicity analysis of the
cross-platform dataset resulted in a larger number of 24 h rhythmic genes than for either of the
platforms alone. Rhythmic parameters estimated based on the cross-platform time series were well
correlated with parameters identified based either on the microarray or the RNA-seq data. Thus, the
normalization and concatenation of time series gene expression data from two different platforms is a
powerful method to identify circadian genes. With this approach, a higher number of technologically
diverse datasets from different platforms can potentially be integrated for meta-analyses. Using the
concatenated dataset, we observed several differences between the primary tumor cell line (SW480) and
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the metastasis-derived cell line (SW620). We identified a differential distribution of gene expression
peak times (phases) between the two cell lines. For the primary tumor-derived cells, the distribution
of phases was covering nearly the whole circadian day (from 0 to 23.6 h), whereas the enriched
pathways in metastasis-derived cells peaked in a relatively narrow time window (4.5 to 10.3 h). Various
cancer-associated cellular pathways were enriched for circadian genes in both cell lines, including the
cell cycle, DNA replication, DNA damage response, all of which are known to be circadian-regulated.
These results obtained in the concatenated data are in line with our previous data based only on the
microarray dataset. In addition, the difference in phase distribution between two cell lines indicated a
phase shift of 2 to 3 h, which suggested that the circadian clock is dysregulated in the metastatic cell
line (SW620). These results are in agreement with previous work from our group [33,39].
3.2. Neurodegeneration-Related Pathways Are Clock-Regulated in the Metastatic CRC Cells
We observed several neurodegenerative disease-related pathways in metastasis-derived cells
enriched for circadian gene sets, which were not identified for the primary tumor-derived cells.
Besides Alzheimer’s disease and Parkinson’s disease, we found a strong association with HD.
Neurodegeneration is the main feature of HD, resulting in a triad of motor, cognitive and psychiatric
symptoms [58]. In contrast, abnormal uncontrolled cell proliferation is the major characteristic of
cancer, placing these two severe diseases at opposite sides of the cell fate spectrum. In line with our
findings, previous studies suggested an almost 80% reduction of cancer incidence in HD patients
compared to the general population [44,45]. We found 27 HD-associated genes in our cancer cell lines,
out of which 26 genes were identified to be oscillating in metastasis-derived SW620 cells and 3 genes
were oscillating significantly in primary tumor-derived SW480 cells. The set of HD-associated genes
oscillating in SW620 cells included genes involved in cell death (CASP3, TP53, CYSC), mitochondrial
oxidative phosphorylation (SOD2, SDHD, NDUFA2, NDUFA4, NDUFA4L2, NDUFAB1, NDUFS3,
UQCR10, and UQCRHL), and gene transcription by RNA polymerase II (POLR2A, POLR2C, POLR2K,
TAFA4, TBP, and TBPL1).
HTT is expressed throughout the body and the mutant protein not only affects the brain but
also peripheral tissues as weight loss, cardiomyopathies and skeletal muscle malfunction have been
described for HD [59]. Interestingly, cancer has been reported to account only for 5% of the leading
causes for death in HD [45]. However, mutant HTT can also contribute to the severity and progression
of a specific cancer type. For example, while HTT regulates the normal development of the mammary
tissue [59,60], mutant HTT expression is pro-metastatic in breast cancer and can accelerate tumor
development through ErbB2/HER2 signaling [61]. Notably, mHTT has been reported to interact
directly with SIRT1, a clock gene, and inhibit its activity [62]. It is interesting to note that we found
significantly more circadian regulated genes in metastatic CRC cells than in primary tumor-derived
cells. Interestingly, MLH1 has been identified as a modifier of HD onset [63] and has also been
associated with higher risk of colorectal cancer [64,65]. In particular, MLH1 plays an important role in
the microsatellite instable biological subtype of colorectal cancer [66]. Microsatellite instability (MSI)
shows different pathological characteristics, as well as poor response to traditional chemotherapeutic
reagents. Surprisingly, we found that HTT oscillated in SW480 cells, but not in SW620 cells, although
its interacting factor, HIP1, oscillated in both cell lines. SOD2 encodes for a protein involved in
reactive oxygen species clearance in mitochondria, and oscillates in SW620 cells. SOD2 has a rhythmic
acetylation that is suppressed in mice with Clock mutation [67]. Remarkably, five genes of the NDUF
family that encodes for mitochondrial enzymes involved in oxidative phosphorylation oscillate in
SW620 cells, but not in SW480 cells. One of them is NDUFS3, a potential biomarker to discriminate
invasive from normal breast cancer [68], whose expression is controlled by the CLOCK gene [69].
3.3. Circadian Regulation of Cancer Hallmarks and Molecular Drug Targets
Perturbations of core-clock genes have been reported to influence the hallmarks of cancer in
different cancer models including the CRC cell line model investigated in this manuscript. Differential
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effects on the cell cycle were reported to be associated to the expression levels of the core-clock gene
BMAL1 [27]. The downregulation of BMAL1 in SW480 cells lead to an increase of cells in the S-phase
and a decrease of cells in the G1-phase, in SW620 cells—where BMAL1 expression is already very low
no significant effect was observed. Thus, decreased expression levels of BMAL1 seems to be associated
with more proliferative scenarios in these CRC cell lines. Moreover, BMAL1 knockdown impacts
proliferation, and apoptosis in a time-dependent manner [39]. Upon knockdown of BMAL1, SW480 cells
proliferate faster than the corresponding control cells and their proliferation profile resembles that of
SW620 cells, leading to the assumption that a dysregulated clock promotes a more metastatic phenotype.
The effect of BMAL1 knockdown on cell viability was shown to be time-dependent for both cell lines,
with an increased viability observed for later time points, with more prominent changes in SW480 cells.
The downregulation of BMAL1 led to significantly lower apoptosis rates for both SW480 and SW620
cells, which is in line with the assumption of the clock acting as a tumor suppressor [70]. This circadian
regulation of cellular processes impacts the time of day of drug administration (chronotherapeutics),
the distribution, metabolism, and excretion of therapeutic agents, and is used to improve the efficiency
of anti-cancer drugs while reducing undesired side effects [71]. The genes that were oscillating in
our analysis are critical elements of pathways that are dysregulated in various types of cancer [72].
Therefore, targeting these genes has been the scope of development of new and more effective cancer
drugs [73]. The link we observe to these genes in our data analysis reveal interesting candidates for
the optimization of cancer treatment. In particular, to link the oscillating genes that are known to
be targets of cancer drugs [7,31], to the hallmarks of cancer-related genes and ECCN genes [32], we
investigated the role of our candidate genes in TCGA colon adenocarcinoma samples. Our analysis of
mutational frequencies revealed core-clock genes including PER1, PER3, ARNTL2, and NR1D1 and two
ECCN genes CREBBP and EP300 to be mutated in more than 4% of the patients. We further performed
a differential gene expression analysis between paired tumor and normal samples which revealed
12 of our candidate genes to be differentially expressed. From those, NR1D1, CSNK2A1, PER3, and
VEGFA showed significant correlation with patient survival. This indicates that refinement of cancer
treatments based on the individual circadian rhythm may provide additional benefits for the therapy
outcome. Although not all of the core-clock genes showed high mutational frequencies within the
TCGA cohort, we did not exclude possible indirect contributions of the circadian clock on the candidate
genes. Therefore, we illustrated the connection of these cancer associated and circadian drug target
genes to the core-clock machinery based on the literature. The intersection between cancer-associated
and circadian genes in both cell lines resulted in three genes, SIRT1, AKT1, and mTOR. SIRT1 is a
well-characterized circadian regulated member of Sirtuins family involved in histone and/or protein
deacetylation [74], and plays an important role in various cancer related processes such as inhibition of
apoptosis for cell survival and oxidative damage or DNA damage induced senescence.
One of the interesting candidate genes identified in our study—Akt1 is both a cancer hallmark
and a relevant circadian drug target gene. Interestingly, the activity of Akt1 was found to depict
circadian rhythms due to periodic fluctuations in its phosphorylation [75]. Akt circadian activity might
also influence other pro-tumorigenic processes such as cellular proliferation and promotion of cell
survival. In the same study, the authors have shown that acute depletion of Cdk2, as well as deletion of
Cyclin A2 or Cdk2 resulted in the decrease of Akt phosphorylation and subsequently its activity, and
suggested that variation in Cyclin A2 may partially explain the pro-tumorigenic activity of Akt [75].
It would be interesting in future work to investigate this mechanism in the context of colorectal cancer.
Previous studies by Sessa and colleagues showed the crucial role of AKT on proper functioning
of the CLOCK by phosphorylation from a specific serine site [76]. More recently, an experimental jet
lag protocol aimed to test the role of chrono-modulated drug delivery for Cdk4/6 inhibitors in mice
revealed a significant upregulation of AKT1 [77]. It is also well known that AKT can influence the
circadian phenotype both via the upstream (PI3K) and downstream substrates such as the transcription
factor FOXO [78]. However, to our knowledge, the potential benefit of chrono-modulation for AKT
targeting has not been studied in the context of colorectal cancer. Also the inhibition of mTOR, as a
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result of hypoxia related acidification of the cellular microenvironment, was found to lead to clock
dysfunction [79]. The mTOR pathway consists of a signaling cascade that serves various crucial cellular
regulatory functions such as metabolism, proliferation, and growth [80]. Accumulating evidence
points to the role of the mTOR pathway in the regulation of the circadian system [81–83], as well as in
various pathologies including cancer [84]. A study with Everolismus, an mTOR inhibitor, showed a
better antitumor efficiency in mice when administered at ZT12.
Next, we aimed to identify the implication of our findings for molecular drug targets. Our
results showed that two well-known drug target genes in cancer therapy, AKT1 and mTOR were
oscillating in both CRC cell lines. Ideal timing is a crucial but underestimated trait in drug development
and the genes that we found to be oscillating in both cell lines are critical elements of frequently
dysregulated pathways in various types of cancer [72]. Therefore, targeting these genes is one of the
aims in the development of new and more effective cancer drugs [73]. The link we observe between
the circadian clock and these genes, in our data analysis, makes them interesting candidates for the
time of day optimization of cancer treatment. In addition to these common drug target pathways,
we identified unique sets of drug target genes in our analysis including members of the RAS family.
NRAS and RRAS, exhibit circadian rhythmicity in SW480 cells. RAS can activate cell cycle regulators
such as the cyclin dependent kinase inhibitor p16 (Ink4a), which results in dysregulation of the cell
cycle. RAS induced activation of Ink4a leads to cell cycle arrest and acts as a tumor-suppressive
mechanism [85]. In addition, perturbations in oncogenic RAS were shown to modulate the circadian
clock in an in vitro CRC model [86]. In a follow-up study with mouse embryonic fibroblast, the authors
found a role for the tumor-suppressors Ink4a and Arf as mediators of RAS induced changes on the
circadian phenotype, which promoted a more cancer-prone scenario in these cells, by enhancing
proliferation [27]. In our current results, NRAS and RRAS exhibit differential circadian expression in
SW480 cells and the metastasis derived cells (SW620). Further experimental validation is required, to
investigate whether the difference observes in the oscillatory behavior of these two target genes, as
a result from the circadian phenotypes of both cells, might have an implication in the tumorigenic
properties of these CRC cells and to which extent are alterations of circadian regulation a putative
driver of tumor progression.
In the metastasis-derived SW620 cells, two members of the ABC transporter superfamily were
found to be oscillating. The overexpression of ABC transporters is known to be involved in multiple
drug resistance which leads to therapy resistance. Interestingly, independently from our dataset,
ABCB1 was among the top candidate genes in our mutation frequency analysis based on TCGA data.
In recent years, it has been reported that tyrosine kinase inhibitors also repress ABC transporters [87,88].
There are various receptor tyrosine kinase inhibitors used in the clinics, some of which have already
been studied for the enhancement of therapeutic response by chrono-modulated fashion. For example,
Erlotinib which is an inhibitor of Ras-Raf-MAPK receptor tyrosine kinase activity was found to be more
effective at ZT1 in contrast to ZT13 in female mice (ZT, Zeitgeber Time is defined as the time of external
or environmental cues that entrain or synchronize an organism’s circadian clock) [89,90]. Another
study showed the enhanced impact of lapatinib, a dual inhibitor of EGFR and Ras-Raf-MAPK cascade,
in male mice when administered at ZT23, resulting in better tumorigenesis inhibition and angiogenesis
compared to ZT13 [31]. Given the results of these previous studies and circadian transcription of two
members of ABC transporters in our metastatic cell line, treatment outcome with receptor tyrosine
kinases could be potentially advanced based on the patient specific circadian rhythm. This might be a
potential solution for a frequent problem in clinics: Therapy resistance and relapse. It should be also
taken into account that the treatment outcome is not solely dependent on the individual chronotype,
but also on additional traits such as age and gender [91]. Therefore, new methodologies should be
developed to study various traits in cancer development within currently available data.
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4. Materials and Methods
4.1. Microarray Data Pre-Processing
Raw microarray expression data of the human CRC cell lines SW480 and SW620 from El-Athman,
Fuhr and Relógio [33] was downloaded from the ArrayExpress database (E-MTAB-5876). The data
was pre-processed for all time points of each dataset as one batch using the RMA methodology [92,93]
as implemented in the oligo package (v1.42.0) [94]. Transcript clusters were annotated with Ensembl
IDs using Affymetrix HTA 2.0 annotation data (hta20transcriptcluster.db, v8.7.0). For genes annotated
by multiple transcript clusters, the transcript cluster with the highest mean expression over all time
points of the respective cell line was chosen to represent gene-level expression.
4.2. RNA-seq Data Pre-Processing
Raw RNA-seq data of the human CRC cell lines SW480 and SW620 from El-Athman, Knezevic,
Fuhr and Relógio [34] was downloaded from the ArrayExpress database (E-MTAB-7779). Quality
control of the 75 bp paired-end reads was performed using FastQC (v0.11.7) [95] and adapter sequences
were cut using Trimmotatic (v0.38) [96] with TruSeq3-PE-2 adapter sequences. Only paired-end reads
were retained. Alignment and quantification of the RNA-seq data was conducted in a tripartite
pipeline that makes use of two prominent tools for the alignment and quantification of RNA-seq data,
STAR (v2.6.0a) [97] and Salmon (v0.10.2) [98], and a combination of both. In the STAR + featureCounts
pipeline, sequencing reads were aligned to the human genome (Homo_sapiens.GRCh38, Ensembl
release 92) using STAR with default parameters. Aligned reads were then assigned to genomic features
and quantified using featureCounts [99] as implemented in the R package Rsubread (v1.34.4) [100].
In the STAR + Salmon pipeline, the genome alignment was translated to transcript coordinates
using STAR with the option—quantMode TranscriptomeSAM. Reads were quantified based on the
STAR transcriptome alignment using Salmon in alignment-based mode with default parameters
and the—seqBias option. In the Salmon pipeline, reads were directly quantified using Salmon in
mapping-based mode with default parameters and the—seqBias option. The transcriptome indices
for Salmon were built based on Homo_sapiens. GRCh38.cdna, Ensembl release 92. For both the
STAR + Salmon and the Salmon pipeline, the resulting transcripts per million (TPM) count tables were
scaled using the tximport package (v1.6.0) [101] by first multiplying TPM by feature length and then
scaling up to the library size (lengthScaledTPM), resulting in summarized gene-level (txOut = FALSE,
based on Ensembl Transcript IDs) count estimates. For all three RNA-seq pipelines, counts were
log2-transformed using the cpm function and applying the TMM method from the R package edgeR
(v3.20.9) [102]. Only genes with at least 0.5 CPM on average over all time points of a cell line were
retained and counts were renormalized using only the selected genes.
4.3. Cross-Platform Normalization and Concatenation of Time Series
To enable a cross-platform concatenation of the time series gene expression data, we applied
Training Distribution Matching (TDM) as implemented in the R package TDM (v0.3) [41]. TDM has
originally been developed for making machine learning applications trained on legacy microarray data
applicable to RNA-seq data. We used the TDM algorithm to transform the RNA-seq data for each cell
line individually, thereby making its distribution comparable to that of the microarray data of the same
cell line, while keeping inter-observation dependencies of the RNA-seq time series intact. A longer
time series (0 to 42 h after synchronization) was produced by first individually normalizing both the
microarray and the TDM-transformed RNA-seq data to the mean of the shared time points (12 to 24 h
after synchronization) and then concatenating both datasets. Values of the overlapping time points
were treated as replicate measurements.
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4.4. Rhythmicity Analysis
For the detection of circadian genes and their parameters (phase and amplitude), the harmonic
regression method was applied as implemented in the R package HarmonicRegression (v1.91) [103],
using the robust option and setting the period to 24 h. For both the microarray and RNA-seq
data, original (not log2-scaled and not TDM-transformed) expression values of commonly expressed
genes between the platform were used as input. For the concatenated data, the normalized and
TDM-transformed time series were used. Harmonic regression p-values were Benjamini-Hochberg
adjusted for multiple testing. Statistical significance for 24 h rhythmic genes was set at q < 0.05 and a
relative amplitude ≥ 0.1.
4.5. Correlation Analysis
For each cell line, correlation of expression values of commonly expressed genes was conducted
between all four pipeline methods (microarray, STAR + featureCounts, STAR + Salmon, Salmon) in a
pairwise manner for samples taken at identical time points, considering only those time points that are
shared between all methods (12–24 h). The resulting Pearson correlation coefficients were averaged
over all time points for each method comparison. Circadian parameters (i.e., phases and relative
amplitudes) of 24 h rhythmic genes were compared between the three datasets (microarray, RNA-seq,
and the concatenation of both) in a pairwise manner. Only genes that were commonly identified to be
24 h rhythmic were considered for the correlation analyses. Circular Pearson correlation coefficients
were computed for phases of 24-h rhythmic genes and statistical significance was tested using the
function core-circular from the R package circular (v0.4-93) for circular statistics [104]. For relative
amplitudes, Pearson correlation coefficients were computed and statistical significance was tested
using the function cor.test from the R package stats.
4.6. Functional Enrichment
Significantly phase-clustered circadian pathways enriched for the 24 h rhythmic genes sets
were detected based on the concatenated dataset were identified by Phase Set Enrichment Analysis
(PSEA) [105]. Phases of 24 h rhythmic genes were rounded to the full hour. Gene sets for KEGG
pathways (c2.cp.kegg.v6.2) were downloaded from the Molecular Signatures database (MSigDB) [106].
The Kuiper test was used to identify circadian pathways against a uniform background distribution.
Pathways containing less than five 24 h rhythmic genes were excluded and statistical significance was
set at q < 0.05.
4.7. Analysis of CRC Data From a Cohort of Patients Retrieved from the TCGA Data Base
Clinical information for colon adenocarcinoma with overall patient survival obtained from The
Cancer Genome Atlas (TCGA) research network established by the National Cancer Institute at the
National Institute of Health (available at https://portal.gdc.cancer.gov). Mutational frequencies in the
TCGA COAD patient population (using 439 samples from PanCancer Atlas all colon adenocarcinoma
data) were plotted using cBio Cancer Genomics Portal (available at http://cbioportal.org) developed
by Memorial Sloan-Kettering Cancer Center [107,108]. Oncoprint functionality used for graphical
representation of mutation frequency summary plots for total number of 92 target genes derived from
our analysis. These included 55 candidate genes curated from our analysis and 39 genes from reduced
Extended Core Clock Network that include genes that oscillate significantly in either of the cell lines
within our concatenated data. When the gene lists were intersected, 2 genes were common in between
ECCN and disease candidate genes, which resulted in 92 unique candidate genes. The differential
gene expression analysis performed using R Studio Bioconductor package TCGAbiolinks [109,110]
package v.2.15.3. FPKM-UQ normalized transcriptome profiling with gene expression quantification
values were downloaded for COAD patients with 439 tumor and 41 normal tissue samples obtained
from the adjacent normal tissue of the patients. The data normalized based on quantile method and
Cancers 2020, 12, 963 19 of 25
the differential expression analysis performed using EdgeR pipeline, which follows a generalized
linear models (glmLRT) functionality. We restricted our analysis for tumor and normal samples that
show a fold change (FC) greater than 1.5 and FDR < 0.05 and regarded the genes pass this cut-off as
differentially expressed. The resulted DE genes were then intersected with our candidate genes list
which resulted in 12 common genes. For these genes we plotted survival curves using a Cox model that
includes coxph (Surv(times,died) ~gene + age) via OncoLnc (available at http://www.oncolnc.org) [111].
The survival data being used in the interactive portal includes clinical data for only patients who
contain all the clinical information needed for the analysis and based on a follow up or survival days
greater than zero. Previous studies revealed contribution of additional clinical parameters to the
benefit provided by chronotherapy (i.e., age and sex). Therefore, in our cox survival analysis we added
patient age as a clinical parameter in addition to gene expression. The patient cohort for the gene
expression level survival plots selected for Colon Adenocarcinoma (COAD) and the expression change
were compared between the top third (33%) and bottom third (33%) of the total dataset which allows
exclusion of overlapping data slices. Based on the mean expression value of the candidate gene, the
change in gene expression levels were categorized as high and low for equal number of patients in the
cohort (n = 145 for high expression group and n = 145 for low expression group).
5. Conclusions
The circadian clock can directly or indirectly regulate and interact with biological events that are
likely to play a role in tumor initiation and progression [112]. These include circadian regulation of the
cell division cycle [27], DNA damage repair [18], metabolism [11], apoptosis, and redox events. A link
between the circadian clock and the hallmarks of cancer has emerged in recent years [6,7,113].
Colorectal cancer is one of the best studied examples for administration of chrono-modulated
chemotherapeutic. Multiple clinical studies showed therapeutic benefits of chronotherapy in CRC
patients with conventional chemotherapeutic reagents such as oxaliplatin [114], irinotecan [115],
5-fluorouracil (5-FU) [116], folinic acid [116] and leucovorin [117], which revealed differential
contribution of additional clinical parameters to the benefit provided by chronotherapy (i.e., age and
sex). Therefore, in our study we aimed to investigate circadian (dys-)regulation in a CRC cellular model
at the transcriptome level. We used two colorectal cell lines derived from the primary tumor cells and
metastasis of the same patient to study circadian properties from time course datasets, including arrays
and sequencing data which were merged and concatenated to generate a data set with a longer time
courses and partly replicated time points. Our approach can be useful for other time series data sets
obtained from different high-throughput platforms.
We observed differentially enriched pathways in SW480 and SW620 cell lines including multiple
neurodegenerative disease-related pathways in the metastasis-derived SW620 cells. We focused on
HD and found 25 HD- associated genes to be circadian expressed in the metastasis cells. We further
investigated the indirect link between these cancer hallmarks genes and circadian drug targets in our
datasets and identified AKT1 and MTOR as potential circadian drug targets for both of our cell lines.
Analyzing gene expression data from a cohort of 439 patients with CRC available in the TCGA
Pan-Cancer colon adenocarcinoma (COAD) study, we strengthened the connection found between
cancer and HD.
Our study, using a cross-platform concatenation of existing circadian data sets, provides a
comprehensive analysis of circadian properties at different stages of colorectal cancer and highlights
their potential impact in a large patient dataset. Further in vitro and in vivo investigation of circadian
disruption and its impact in the time-dependent regulation of the target genes identified in our analysis,
including the functional outcomes of such perturbations on cell cycle, proliferation and apoptosis,
may contribute to design individualized cancer treatment regimens, which consider the individual
circadian rhythm of patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/4/963/s1,
Figure S1: Mapping rates and number of expressed genes for different methods and cut-offs, Figure S2: RNA-seq
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expression data before and after cross-platform normalization, Figure S3: Comparison of circadian parameters
between sets of 24 h rhythmic genes identified for different methods, Figure S4: OncoPrint mutational frequency
summary all candidate genes (including cancer hallmark associated genes, circadian drug targets, HD and ECCN)
in TCGA pan-cancer colon adenocarcinoma study, Figure S5: Cox regression-based survival curves for 12 genes
found common in differentially expressed genes analysis and our candidate genes list, Table S1: List of Genes
Identified from PSEA for HD, Table S2: List of 55 genes found to be HD-related, cancer hallmark genes that are
associated with the circadian clock and circadian drug target genes, Table S3: Literature references for Figure 7A,
Table S4: The list of genes included in the Extended Core Clock Network, Table S5: Differentially expressed genes
(DEG) between tumor and adjacent normal tissue samples (FC > 1.5 and FDR < 0.01).
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